Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation

Akira Marui, Akihiro Kanematsu, Kenichi Yamahara, Kazuhiko Doi, Toshihiro Kushibiki, Masaya Yamamoto, Hiroshi Itoh, Tadashi Ikeda, Yasuhiko Tabata, Masashi Komeda

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: The present study investigated whether the simultaneous application of basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) enhances blood vessel formation in murine ischemic hindlimb compared with bFGF or HGF applied alone. Methods: Unilateral hindlimb ischemia was created in C57BL/6 mice. Hindlimb blood flow was evaluated by laser Doppler perfusion image index (LDPII) (ratio (%) of ischemic-to-normal-limb blood flow). The ischemic limbs were treated with bFGF and HGF separately, or bFGF and HGF together, and their therapeutic effects were assessed. Collagen microspheres (CM) were used as a sustained-release carrier for bFGF and HGF. Results: A single intramuscular injection of 5 μg or less of bFGF-incorporated CM (bFGF/CM) into the ischemic limb did not significantly increase the LDPII compared with the control (no treatment) 4 weeks after the treatment. Similarly, 20 μg or less of HGF/CM did not increase LDPII. Based on these results, we compared the dual release of CM incorporating 5 μg of bFGF and 20 μg of HGF with either the single release of 5 μg of bFGF/CM alone or 20 μg of HGF/CM alone. The LDPII of the dual release (94.2% ± 10.9%) was higher than either single release (51.2% ± 5.8% or 52.5% ± 8.0%, P <. 01). Furthermore, the LDPII in the dual release (94.2% ± 10.9%) was equivalent to that with 80 μg of bFGF/CM (95.1% ± 7.6%) alone or 80 μg of HGF/CM (92.8% ± 7.6%) alone. A histologic evaluation at 4 weeks showed capillary density in the dual release (868 ± 173 vessels/mm 2) was higher than that in either single release (204 ± 68 vessels/mm2 or 185 ± 98 vessels/mm2, P < .01). The percentage of mature vessels assessed by α-smooth muscle actin staining was also higher in the dual release (43.8% ± 7.8% vs 9.5% ± 3.0% or 11.7% ± 3.8%, respectively; P <. 01). Conclusions: This study demonstrates that the sustained dual release of a lower dose of bFGF and HGF from a carrier matrix can achieve equivalent blood perfusion recovery and more mature vasculature in the ischemic limb than a higher dose of bFGF or HGF alone. This approach may be a highly promising strategy for the future treatment of peripheral vascular disease.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalJournal of Vascular Surgery
Volume41
Issue number1
DOIs
Publication statusPublished - 2005 Jan
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Fibroblast Growth Factor 2
Blood Vessels
Microspheres
Collagen
Perfusion
Lasers
Hindlimb
Extremities
Peripheral Vascular Diseases
Intramuscular Injections
Therapeutic Uses
Inbred C57BL Mouse
Smooth Muscle
Actins
Ischemia
Staining and Labeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. / Marui, Akira; Kanematsu, Akihiro; Yamahara, Kenichi; Doi, Kazuhiko; Kushibiki, Toshihiro; Yamamoto, Masaya; Itoh, Hiroshi; Ikeda, Tadashi; Tabata, Yasuhiko; Komeda, Masashi.

In: Journal of Vascular Surgery, Vol. 41, No. 1, 01.2005, p. 82-90.

Research output: Contribution to journalArticle

Marui, A, Kanematsu, A, Yamahara, K, Doi, K, Kushibiki, T, Yamamoto, M, Itoh, H, Ikeda, T, Tabata, Y & Komeda, M 2005, 'Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation', Journal of Vascular Surgery, vol. 41, no. 1, pp. 82-90. https://doi.org/10.1016/j.jvs.2004.10.029
Marui, Akira ; Kanematsu, Akihiro ; Yamahara, Kenichi ; Doi, Kazuhiko ; Kushibiki, Toshihiro ; Yamamoto, Masaya ; Itoh, Hiroshi ; Ikeda, Tadashi ; Tabata, Yasuhiko ; Komeda, Masashi. / Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. In: Journal of Vascular Surgery. 2005 ; Vol. 41, No. 1. pp. 82-90.
@article{1e9a08a510b24850b61d04131c437251,
title = "Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation",
abstract = "Objective: The present study investigated whether the simultaneous application of basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) enhances blood vessel formation in murine ischemic hindlimb compared with bFGF or HGF applied alone. Methods: Unilateral hindlimb ischemia was created in C57BL/6 mice. Hindlimb blood flow was evaluated by laser Doppler perfusion image index (LDPII) (ratio ({\%}) of ischemic-to-normal-limb blood flow). The ischemic limbs were treated with bFGF and HGF separately, or bFGF and HGF together, and their therapeutic effects were assessed. Collagen microspheres (CM) were used as a sustained-release carrier for bFGF and HGF. Results: A single intramuscular injection of 5 μg or less of bFGF-incorporated CM (bFGF/CM) into the ischemic limb did not significantly increase the LDPII compared with the control (no treatment) 4 weeks after the treatment. Similarly, 20 μg or less of HGF/CM did not increase LDPII. Based on these results, we compared the dual release of CM incorporating 5 μg of bFGF and 20 μg of HGF with either the single release of 5 μg of bFGF/CM alone or 20 μg of HGF/CM alone. The LDPII of the dual release (94.2{\%} ± 10.9{\%}) was higher than either single release (51.2{\%} ± 5.8{\%} or 52.5{\%} ± 8.0{\%}, P <. 01). Furthermore, the LDPII in the dual release (94.2{\%} ± 10.9{\%}) was equivalent to that with 80 μg of bFGF/CM (95.1{\%} ± 7.6{\%}) alone or 80 μg of HGF/CM (92.8{\%} ± 7.6{\%}) alone. A histologic evaluation at 4 weeks showed capillary density in the dual release (868 ± 173 vessels/mm 2) was higher than that in either single release (204 ± 68 vessels/mm2 or 185 ± 98 vessels/mm2, P < .01). The percentage of mature vessels assessed by α-smooth muscle actin staining was also higher in the dual release (43.8{\%} ± 7.8{\%} vs 9.5{\%} ± 3.0{\%} or 11.7{\%} ± 3.8{\%}, respectively; P <. 01). Conclusions: This study demonstrates that the sustained dual release of a lower dose of bFGF and HGF from a carrier matrix can achieve equivalent blood perfusion recovery and more mature vasculature in the ischemic limb than a higher dose of bFGF or HGF alone. This approach may be a highly promising strategy for the future treatment of peripheral vascular disease.",
author = "Akira Marui and Akihiro Kanematsu and Kenichi Yamahara and Kazuhiko Doi and Toshihiro Kushibiki and Masaya Yamamoto and Hiroshi Itoh and Tadashi Ikeda and Yasuhiko Tabata and Masashi Komeda",
year = "2005",
month = "1",
doi = "10.1016/j.jvs.2004.10.029",
language = "English",
volume = "41",
pages = "82--90",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation

AU - Marui, Akira

AU - Kanematsu, Akihiro

AU - Yamahara, Kenichi

AU - Doi, Kazuhiko

AU - Kushibiki, Toshihiro

AU - Yamamoto, Masaya

AU - Itoh, Hiroshi

AU - Ikeda, Tadashi

AU - Tabata, Yasuhiko

AU - Komeda, Masashi

PY - 2005/1

Y1 - 2005/1

N2 - Objective: The present study investigated whether the simultaneous application of basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) enhances blood vessel formation in murine ischemic hindlimb compared with bFGF or HGF applied alone. Methods: Unilateral hindlimb ischemia was created in C57BL/6 mice. Hindlimb blood flow was evaluated by laser Doppler perfusion image index (LDPII) (ratio (%) of ischemic-to-normal-limb blood flow). The ischemic limbs were treated with bFGF and HGF separately, or bFGF and HGF together, and their therapeutic effects were assessed. Collagen microspheres (CM) were used as a sustained-release carrier for bFGF and HGF. Results: A single intramuscular injection of 5 μg or less of bFGF-incorporated CM (bFGF/CM) into the ischemic limb did not significantly increase the LDPII compared with the control (no treatment) 4 weeks after the treatment. Similarly, 20 μg or less of HGF/CM did not increase LDPII. Based on these results, we compared the dual release of CM incorporating 5 μg of bFGF and 20 μg of HGF with either the single release of 5 μg of bFGF/CM alone or 20 μg of HGF/CM alone. The LDPII of the dual release (94.2% ± 10.9%) was higher than either single release (51.2% ± 5.8% or 52.5% ± 8.0%, P <. 01). Furthermore, the LDPII in the dual release (94.2% ± 10.9%) was equivalent to that with 80 μg of bFGF/CM (95.1% ± 7.6%) alone or 80 μg of HGF/CM (92.8% ± 7.6%) alone. A histologic evaluation at 4 weeks showed capillary density in the dual release (868 ± 173 vessels/mm 2) was higher than that in either single release (204 ± 68 vessels/mm2 or 185 ± 98 vessels/mm2, P < .01). The percentage of mature vessels assessed by α-smooth muscle actin staining was also higher in the dual release (43.8% ± 7.8% vs 9.5% ± 3.0% or 11.7% ± 3.8%, respectively; P <. 01). Conclusions: This study demonstrates that the sustained dual release of a lower dose of bFGF and HGF from a carrier matrix can achieve equivalent blood perfusion recovery and more mature vasculature in the ischemic limb than a higher dose of bFGF or HGF alone. This approach may be a highly promising strategy for the future treatment of peripheral vascular disease.

AB - Objective: The present study investigated whether the simultaneous application of basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) enhances blood vessel formation in murine ischemic hindlimb compared with bFGF or HGF applied alone. Methods: Unilateral hindlimb ischemia was created in C57BL/6 mice. Hindlimb blood flow was evaluated by laser Doppler perfusion image index (LDPII) (ratio (%) of ischemic-to-normal-limb blood flow). The ischemic limbs were treated with bFGF and HGF separately, or bFGF and HGF together, and their therapeutic effects were assessed. Collagen microspheres (CM) were used as a sustained-release carrier for bFGF and HGF. Results: A single intramuscular injection of 5 μg or less of bFGF-incorporated CM (bFGF/CM) into the ischemic limb did not significantly increase the LDPII compared with the control (no treatment) 4 weeks after the treatment. Similarly, 20 μg or less of HGF/CM did not increase LDPII. Based on these results, we compared the dual release of CM incorporating 5 μg of bFGF and 20 μg of HGF with either the single release of 5 μg of bFGF/CM alone or 20 μg of HGF/CM alone. The LDPII of the dual release (94.2% ± 10.9%) was higher than either single release (51.2% ± 5.8% or 52.5% ± 8.0%, P <. 01). Furthermore, the LDPII in the dual release (94.2% ± 10.9%) was equivalent to that with 80 μg of bFGF/CM (95.1% ± 7.6%) alone or 80 μg of HGF/CM (92.8% ± 7.6%) alone. A histologic evaluation at 4 weeks showed capillary density in the dual release (868 ± 173 vessels/mm 2) was higher than that in either single release (204 ± 68 vessels/mm2 or 185 ± 98 vessels/mm2, P < .01). The percentage of mature vessels assessed by α-smooth muscle actin staining was also higher in the dual release (43.8% ± 7.8% vs 9.5% ± 3.0% or 11.7% ± 3.8%, respectively; P <. 01). Conclusions: This study demonstrates that the sustained dual release of a lower dose of bFGF and HGF from a carrier matrix can achieve equivalent blood perfusion recovery and more mature vasculature in the ischemic limb than a higher dose of bFGF or HGF alone. This approach may be a highly promising strategy for the future treatment of peripheral vascular disease.

UR - http://www.scopus.com/inward/record.url?scp=19944433012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433012&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2004.10.029

DO - 10.1016/j.jvs.2004.10.029

M3 - Article

VL - 41

SP - 82

EP - 90

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 1

ER -